Ractigen Therapeutics to Present Duchenne Muscular Dystrophy RNA Data

Ractigen Therapeutics has been selected to present first-in-human data on its RNA activation therapy for Duchenne muscular dystrophy (DMD). The presentation will be given as a late-breaking oral session at the 31st Annual Congress of the World Muscle Society, highlighting the findings' immediate significance to the field.

The late-breaking designation is reserved for results deemed by the program committee to be of immediate importance. The presentation is expected to provide the first clinical evidence that a small activating RNA (saRNA) molecule can effectively activate muscle protein production in patients with DMD. This genetic disorder leads to progressive muscle weakness and degeneration.

Duchenne muscular dystrophy is a severe, inherited condition primarily affecting boys, with an incidence of approximately 1 in 3,500 to 5,000 live male births. Current treatments focus on managing symptoms and slowing disease progression, but curative therapies remain elusive. Novel therapeutic approaches, such as Ractigen's saRNA technology, offer potential for more targeted treatments.

The World Muscle Society Congress convenes leading researchers and clinicians in the field of neuromuscular diseases. Ractigen's presentation is anticipated to draw significant interest as it may represent a new therapeutic avenue for DMD, aimed at addressing the underlying disease mechanism. Further details on the presentation timing and content will be available in the congress program.